NextCure Inc
NXTC
NASDAQ
Biotechnology
$8.21
USD
-0.07 (-0.85%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $38.08M
Volume 261.7K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-42.75M
TTM
+29.8%
YoY
Operating Cash Flow
$-36.98M
TTM
+31.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 3.2 | 2.8 | 3.0 | 3.3 | 2.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 5.1 |
Total Operating Expenses | 27.3 | 8.9 | 9.8 | 10.1 | 15.1 |
Operating Income | -27.3 | -8.9 | -9.8 | -10.1 | -15.1 |
EBITDA | -26.7 | -8.4 | -9.4 | -9.8 | -9.7 |
Other Income / Expense | 0.5 | 0.3 | 0.3 | 0.3 | 0.2 |
Total Other Income / Expense | 0.5 | 0.3 | 0.3 | 0.3 | 0.2 |
Income Before Income Taxes | -26.8 | -8.6 | -9.4 | -9.8 | -14.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -26.8 | -8.6 | -9.4 | -9.8 | -14.9 |
Consolidated Net Income / Loss | -26.8 | -8.6 | -9.4 | -9.8 | -14.9 |
Net Income Attributable to Common Shareholders | -26.8 | -8.6 | -9.4 | -9.8 | -14.9 |
Basic EPS | -$11.29 | -$3.22 | -$2.37 | -$1.87 | -$2.80 |
Diluted EPS | -$11.29 | -$3.22 | -$2.37 | -$1.87 | -$2.80 |
Basic Shares Outstanding | 2.4M | 2.7M | 4.0M | 5.2M | 5.3M |
Diluted Shares Outstanding | 2.4M | 2.7M | 4.0M | 5.2M | 5.3M |